Recent Company News

• 11:12 AM ET May 15, 2026
  

  Bayer announces that Primary results from the Phase II ARASEC trial show that NUBEQA plus ADT showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with mCSPC (€37.85, -0.33)

• 01:57 PM ET May 06, 2026
  

  FDA approves Tessie for noise aversion and separation anxiety in dogs (€71.00, 0.00)

• 04:13 AM ET Apr 24, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 08:35 AM ET Apr 23, 2026
  

  Transcript Intelligence: Orion Q1 Earnings Themes

• 08:35 AM ET Apr 23, 2026
  

  Transcript Intelligence: Orion Q1 Earnings Guidance

• 08:35 AM ET Apr 23, 2026
  

  Transcript Intelligence: Orion Q1 Earnings Q&A

• 05:04 AM ET Apr 23, 2026
  

  Orion reports Q1 EPS €0.64 vs FactSet €0.71 [7 est, €0.62-0.96]; specifies FY26 outlook (€70.10, -3.25)

• 02:14 AM ET Apr 23, 2026
  

  Orion launches Phase 1B/2 TEADCO basket trial of ODM-212 in combination therapies for advanced solid tumours (€73.35, 0.00)

• 03:50 AM ET Apr 20, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (41 total)

• 04:57 PM ET Apr 19, 2026
  

  FDA grants orphan drug designation to Orion Corp for treatment of mesothelioma (€75.05, 0.00)